RoyGulickMD

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Gulick

Dr. Roy Gulick is an infectious disease specialist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 31 years. Dr. Gulick accepts several types of health insurance, listed below. He is one of 141 doctors at New York-Presbyterian Hospital and one of 42 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Infectious Disease. He has more than 100 publications and over 500 citings.

Office
1315 York Avenue
Mezzanine
New York, NY 10021
Book by Phone+1(928) 325-1630
Is this information wrong?

Education & Training

School of Public Health, Harvard UniversityM.P.H., 1991 - 1993
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1990 - 1991
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1986 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1986
Johns Hopkins UniversityB.A., 1978 - 1982

Certifications & Licensure

NY State Medical License 1988 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Lifetime Achievement Award “for his invaluable contributions in the field of HIV medicine, medical education, and research” HIV Congress, 2012
Clinical Educator Award HIV Medical Association, 2012
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Research in Action Award Treatment Action Group, 2009
Fellow Infectious Diseases Society of America, 2009
Elected Member The American Society for Clinical Investigation, 2006
Clinical Infectious Diseases Award for Outstanding Review 2006
Excellence in Teaching Award (Advanced Basic Science Course) Weill Cornell Medical College, 2005
Advisory Committee Service Award in Recognition of Distinguished Service U.S. Food and Drug Administration, 2005
Mid-Career Investigator Award in Patient-Oriented Research (K24) National Institute of Allergy and Infectious Disease, National Institutes of Health, 2003
Companero (Friend) Award, for commitment to HIV/AIDS research Latino Commission on AIDS, New York, NY, 2002
Most Scientifically Innovative Presentation Second International Workshop on Salvage Therapy for HIV Infection; Toronto, Canada, 1999
Alpha Omega Alpha National Medical Honor Society, Columbia College of Physicians and Surgeons, 1986
Omicron Delta Kappa National Leadership Fraternity, Johns Hopkins University, 1981
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
Completed
Not Applicable
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
Completed
Phase 2
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
Completed
Phase 2
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
Completed
Phase 2
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
Completed
Phase 3
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients Start of enrollment: 2004 May 01
Completed
Phase 2
Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection Start of enrollment: 2005 Mar 01
Terminated
Phase 4
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression Start of enrollment: 2009 Jan 01
Completed
Not Applicable
Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Recruiting
Roles: Contact, Principal Investigator
HIV Adherence Bottle Intervention Trial Start of enrollment: 2015 May 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

5 citations
Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries.
Stanley E Cooper, Joshua Rosenblatt, Roy M Gulick> ;Clinical Infectious Diseases. 2022 Nov 21
1 citations
Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
Todd T. Brown, Krista Yuhas, Kenneth H. Mayer, Raphael J. Landovitz, Mark A. Marzinke, Craig W. Hendrix, Ying Q. Chen, Karen L. Klingman, Wairimu Chege, Marybeth McCau...> ;The Journal of Antimicrobial Chemotherapy. 2021 Nov 13
Managing HIV Treatment Failure: Time to REVAMP?
Roy M. Gulick, Marshall J. Glesby> ;Annals of Internal Medicine. 2021 Oct 26
4 citations
Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence.
Marshall J. Glesby, Roy M. Gulick> ;Annals of Internal Medicine. 2021 Aug 17
252 citations
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho, Robinson Cabello, Suwat Chariyalertsak, Eileen F. Dunne, Ian ...> ;The New England Journal of Medicine. 2021 Aug 11
1 citations
HIV: Closing the Mortality Gap.
Marshall J. Glesby, Roy M. Gulick> ;Annals of Internal Medicine. 2021 Jul 6
13 citations
Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.
Safia S Kuriakose, Kanal Singh, Alice K. Pau, Eric S. Daar, Rajesh T. Gandhi, Pablo Tebas, Laura Evans, Roy M. Gulick, H. Clifford Lane, Henry Masur, Judith A. Aberg, ...> ;Annals of Internal Medicine. 2021 Jun 15
7 citations
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria.
Jesse Fajnzylber, Radwa Sharaf, John N. Hutchinson, Evgenia Aga, Ronald J. Bosch, Wendy Hartogensis, Jeffrey M. Jacobson, Elizabeth Connick, Paul A. Volberding, Daniel...> ;AIDS. 2021 Jun 14
8 citations
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults.
Binglan Li, Yogasudha Veturi, Anurag Verma, Yuki Bradford, Eric S. Daar, Roy M. Gulick, Sharon A. Riddler, Gregory K. Robbins, Jeffrey L. Lennox, David W. Haas, Maryly...> ;Plos Genetics. 2021 Apr 26
8 citations
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
Rogers Sekabira, Ian McGowan, Krista Yuhas, Rhonda M. Brand, Mark A. Marzinke, Yukari C. Manabe, Ian Frank, Joseph J. Eron, Raphael J. Landovitz, Peter A. Anton, Ross ...> ;AIDS. 2021 Apr 6
12 citations
Antiretroviral Drug Activity and Potential for Pre-Exposure Prophylaxis Against COVID-19 and HIV Infection
Dennis C Copertino, Bruno C Casado Lima, Rodrigo R.R. Duarte, Timothy R. Powell, Christopher E. Ormsby, Timothy J. Wilkin, Roy M. Gulick, Miguel de Mulder Rougvie, Dou...> ;Journal of Biomolecular Structure & Dynamics. 2021 Mar 18
4 citations
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
Khanh Pham, Heidi Torres, Michael J. Satlin, Parag Goyal, Roy M. Gulick> ;Rheumatology Advances in Practice. 2021 Mar 2
1 citations
The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply.
Yuanlin Song, Chaomin Wu, Xiaoyan Chen> ;JAMA Internal Medicine. 2021 Jan 1
42 citations
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
Alice K. Pau, Judith A. Aberg, Jason V. Baker, Pamela S. Belperio, Craig M. Coopersmith, Page Crew, Birgit Grund, Roy M. Gulick, Carly Harrison, Arthur Y. Kim, H. Clif...> ;Annals of Internal Medicine. 2021 Jan 1
3 citations
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment
Grant B Ellsworth, Leah A Burke, Martin T. Wells, Satish Mishra, Matthew Caffrey, David Liddle, Malika L. Madhava, Curtis O'Neal, Peter L. Anderson, Lane R. Bushman, L...> ;Journal of Acquired Immune Deficiency Syndromes. 2021 Jan 1
2 citations
The Uncertain Role of Corticosteroids in the Treatment of COVID-19.
Grant B Ellsworth, Marshall J. Glesby, Roy M. Gulick> ;JAMA Internal Medicine. 2021 Jan 1
18 citations
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve.
Robert A. DeSimone, Victoria Costa, Kathleen Kane, Jorge L Sepulveda, Grant B Ellsworth, Roy M. Gulick, Jason Zucker, Magdalena E Sobieszcyk, Joseph E. Schwartz, Melis...> ;Transfusion. 2021 Mar 1
64 citations
Obesity and COVID-19 in New York City: A Retrospective Cohort Study.
Parag Goyal, Joanna Bryan Ringel, Mangala Rajan, Justin J Choi, Laura C. Pinheiro, Han A Li, Graham T Wehmeyer, Mark N. Alshak, Assem Jabri, Edward J. Schenck, Ruijun ...> ;Annals of Internal Medicine. 2020 Nov 17
7 citations
Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City.
Roy M. Gulick, Magdalena E. Sobieszczyk, Donald W. Landry, Anthony N. Hollenberg> ;The Journal of Clinical Investigation. 2020 Sep 1
27 citations
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Michael Leonard, Zinhle Cindi, Yuki Bradford, Kassem Bourgi, John R. Koethe, Megan Turner, Jamison Norwood, Beverly O. Woodward, Husamettin Erdem, Rebecca Basham, Paxt...> ;Clinical Infectious Diseases. 2021 Oct 5
33 citations
COVID-19 in hospitalized adults with HIV
Kate Stoeckle, Carrie D Johnston, Deanna Jannat-Khah, Samuel C. Williams, Tanya M Ellman, Mary A. Vogler, Roy M. Gulick, Marshall J. Glesby, Justin J Choi> ;Open Forum Infectious Diseases. 2020 Aug 1
15 citations
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
Michael J. Satlin, Parag Goyal, Reed Magleby, Grace A. Maldarelli, Khanh Pham, Maiko Kondo, Edward J. Schenck, Hanna Rennert, Lars F. Westblade, Justin J Choi, Monika ...> ;Plos One. 2020 Jul 23
908 citations
Severe Covid-19
Roy M. Gulick, Fernando J. Martinez> ;The New England Journal of Medicine. 2020 May 15
2 citations
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
Babafemi Taiwo, Miguel E. Quiñones-Mateu, Kimberly Y. Smith, Lu Zheng, Roy M. Gulick, Amesika N. Nyaku, Paul E. Sax, Belinda Ha, Johnstone Kumwenda, Maxine Olefsky, Ca...> ;AIDS Research and Human Retroviruses. 2020 Apr 9
1 citations
Drug Costs: What Can Infectious Diseases Physicians Do?
Shashi N Kapadia, Roy M. Gulick> ;The Journal of Infectious Diseases. 2020 Feb 18
Join now to see all

Journal Articles

Combination Therapy with Anti-HIV-1 Antibodies Maintains Viral Suppression
Michael S Seaman, Katrina Millard, Marina Caskey, Michel C Nussenzweig, Roy M Gulick, Thiago Y Oliveira, Nature
Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals
Roy M Gulick, Thiago Y Oliveira, Marina Caskey, Michel C Nussenzweig, Michael S Seaman, Katrina Millard, Nature
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients
Gulick RM, Fatkenheuer G, Burnside R, Hardy WD, Nelson MR, Goodrich J, Mukwaya G, Portsmouth S, Heera JR, JAIDS, 1/1/2014
Modeling immunologic endpoints as a function of time of switch to second-line ART with incomplete data on switching times
Johnson BA, Ribaudo H, Gulick RM, Eron JJ, Biometrics, 1/1/2013
Invasive meningococcal disease in men who have sex with men
Simon MS, Weiss D, Gulick RM, Ann Intern Med, 1/1/2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS Clinical Trials Group (ACTG) study analysis
Ribaudo HJ, Smith KY, Robbins GK, Flexner C, Haubrich R, Chen Y, Fischl MA, Schackman BR, Riddler SA, Gulick RM, Clin Infect Dis, 1/1/2013
Regulatory T cells and the risk of CMV end-organ disease in AIDS patients
Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Collier AC, Behm T, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson M, JAIDS, 1/1/2013
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug
Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, J Virol, 1/1/2012
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development
Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, HIV Clin Trials, 1/1/2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists
Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Antimicrob Agents Chemother, 1/1/2012
Novel clinical trials designs for the development of new antiretroviral agents
Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, AIDS, 1/1/2012
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures
Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, J Virol, 1/1/2012
Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti
Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, J Intern AIDS Soc, 1/1/2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256
Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR, J Infect Dis, 1/1/2012
Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, J Am Stat Assoc, 1/1/2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Pharmacogenet Genomics, 1/1/2012
CCR5 antagonism in HIV infection: Current concepts and future opportunities
Wilkin TJ, Gulick RM, Ann Rev Med, 1/1/2012
Next-generation oral preexposure prophlaxis: beyond tenofovir
Abraham BK, Gulick R, Curr Opin HIV AIDS, 1/1/2012
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in A...
Grady BJ, Torstenson ES, McLaren PJ, DE Bakker PI, Haas DW, Robbins GK, Gulick RM, Haubrich R, Ribaudo H, Ritchie MD, Pac Symp Biocomput, 1/1/2011
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes D, Stevenson M, PLoS Pathogens, 1/1/2011
Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity
Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, Chan ES, Heera J, Chapman D, Spritzler J, Reeves JD, Gulick RM, Coakley E, Clin Infect Dis, 1/1/2011
Change in high-sensitivity C-reactive protein (hsCRP) levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ, AIDS Res Hum Retroviruses, 1/1/2011
Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chene G, D'Ar..., J Acquir Immune Defic Syndr, 1/1/2011
Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases
Haas DW, Kuritzkes D, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich ..., HIV Clin Trials, 1/1/2011
Join now to see all

Press Mentions

CDC Warns of Rise in Drug-Resistant Stomach Bug – NBC ChicagoFebruary 28th, 2023
The CDC Warns of a Rise in Drug-Resistant Shigella BacteriaFebruary 27th, 2023
A Public Health Success Story: How the Mpox Crisis Was Controlled Within 6 MonthsFebruary 2nd, 2023
Join now to see all

Hospital Affiliations

New York-Presbyterian HospitalNew York, New York
New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian/Columbia University Irving Medical CenterNew York, New York

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida BlueSelect
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
Great West PPO
Healthfirst New York
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment